Tesamorelin is a 44-amino-acid GHRH analog designed to restore endogenous growth-hormone output through GHRH-receptor agonism, with study applications focused on visceral adipose accumulation and metabolic profiles. Its full-length structure distinguishes it from shorter secretagogues in comparative endocrinology research. This product is a white lyophilized powder at confirmed purity in a sealed vial, and lot-level quality documentation accompanies every shipment. The product maintains stability for extended periods when stored frozen or refrigerated in its original sealed container, and reconstituted solutions should follow your validated protocol. We supply customers across academic, biotech and industrial sectors, and our export department coordinates documentation, customs and courier selection for each destination country.

Tesamorelin's mechanism of action involves selective activation of the growth hormone-releasing hormone (GHRH) receptor, thereby stimulating the pituitary gland to release endogenous growth hormone (GH) in a physiologically relevant manner. This targeted stimulation has shown promise in clinical settings for reducing abdominal visceral fat, a key marker of metabolic syndrome, and improving insulin sensitivity, lipid profiles, and overall metabolic health. Preclinical and early-phase clinical studies have further explored its potential in conditions associated with GH deficiency or dysregulation, including certain forms of obesity and age-related metabolic decline.
Our commitment to quality extends beyond product supply; we provide comprehensive technical support, including detailed reconstitution guidelines, stability data under various storage conditions, and batch-specific certificates of analysis. For research applications, tesamorelin is often used as a tool compound to investigate GHRH receptor signaling pathways, GH secretion dynamics, and downstream metabolic effects in cell culture and animal models. Custom synthesis and formulation options are available to meet specific experimental requirements, ensuring flexibility for diverse research objectives.
In addition to academic and biotech partnerships, we collaborate with pharmaceutical companies to advance tesamorelin-based therapies through preclinical development and into early-stage clinical trials. Our team of scientists and regulatory experts works closely with clients to navigate complex regulatory landscapes, ensuring compliance with international standards for research and therapeutic product development. Whether supporting basic science discovery or translational research, we strive to deliver reliable, high-quality products and services that drive innovation in endocrinology and metabolic research.